NFDI4DS | UHH-SEMS - Publication Details

Nikolaos Katsivelos

ORCID: 0009-0004-7955-1119

Publications

Citations

Views

---

Saved

---

About

Contact & Profiles

A5040258817

Research Areas

Hematopoietic Stem Cell Transplantation
Mesenchymal stem cell research
Pancreatic and Hepatic Oncology Research
Cardiovascular Syncope and Autonomic Disorders
CAR-T cell therapy research
Cardiac pacing and defibrillation studies
Heart Failure Treatment and Management
IL-33, ST2, and ILC Pathways
Virus-based gene therapy research
Immune Cell Function and Interaction
Neuroendocrine Tumor Research Advances
Renal Transplantation Outcomes and Treatments
Cardiovascular Function and Risk Factors
Antifungal resistance and susceptibility
Biomedical Ethics and Regulation
Gastric Cancer Management and Outcomes
Hemodynamic Monitoring and Therapy
Diabetes and associated disorders
Childhood Cancer Survivors' Quality of Life
Respiratory Support and Mechanisms
Acute Lymphoblastic Leukemia research
Autoimmune and Inflammatory Disorders Research

Icahn School of Medicine at Mount Sinai
2023-2024

The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD

OPENALEX - Publications

Zachariah DeFilipp Haesook T. Kim Nikolaos Spyrou Nikolaos Katsivelos Steven Kowalyk and 22 more

The significance of biomarkers in second-line treatment for acute graft-versus-host disease (GVHD) has not been well characterized. We analyzed clinical data and serum samples at the initiation systemic GVHD from 167 patients 17 centers Mount Sinai Acute International Consortium (MAGIC) between 2016 2021. Sixty-two received ruxolitinib-based therapy, whereas 102 other agents. In agreement with prospective trials, ruxolitinib resulted a higher day 28 (D28) overall response Frate than...

10.1182/bloodadvances.2024012561 article EN cc-by-nc-nd Blood Advances 2024-06-28

Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis

OPENALEX - Publications

Yu Akahoshi Nikolaos Spyrou Matthias Hoepting Paibel Aguayo‐Hiraldo Francis Ayuk and 31 more

Abstract The absence of a standardized definition for graft-versus-host disease (GVHD) flares and data on its clinical course are significant concerns. We retrospectively evaluated 968 patients across 23 Mount Sinai Acute GVHD International Consortium (MAGIC) transplant centers who achieved complete response (CR) or very good partial (VGPR) within 4 weeks treatment. cumulative incidence 6 months was 22%, were associated with higher risk nonrelapse mortality (NRM; adjusted hazard ratio [aHR],...

10.1182/bloodadvances.2023012091 article EN cc-by-nc-nd Blood Advances 2024-02-07

Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD

OPENALEX - Publications

Yu Akahoshi Nikolaos Spyrou Daniela Weber Paibel Aguayo‐Hiraldo Francis Ayuk and 30 more

10.1182/blood.2024025106 article EN Blood 2024-07-05

The utility of biomarkers in acute GVHD prognostication

OPENALEX - Publications

Nikolaos Spyrou Yu Akahoshi Francis Ayuk Ernst Holler Hannah Choe and 29 more

10.1182/bloodadvances.2023009929 article EN cc-by-nc-nd Blood Advances 2023-08-31

A Day 14 Endpoint for Acute GVHD Clinical Trials

OPENALEX - Publications

Nikolaos Spyrou Yu Akahoshi Steven Kowalyk George Morales Rahnuma Beheshti and 36 more

The overall response (ORR) rate 28 days after treatment has been adopted as the primary endpoint for clinical trials of acute graft versus host disease (GVHD). However, physicians often need to modify immunosuppression earlier than day (D) 28, and non-relapse mortality (NRM) does not always correlate with ORR at D28. We studied 1144 patients that received systemic GVHD in Mount Sinai Acute International Consortium divided them into a training set (n=764) validation (n=380). used recursive...

10.1016/j.jtct.2024.01.079 article EN cc-by Transplantation and Cellular Therapy 2024-02-04

The Phase 2 Stargaze Trial of the Glucagon-like Peptide 2 (GLP-2) Analog Apraglutide in Combination with Ruxolitinib for Steroid-Refractory Gastrointestinal (GI) Acute Graft-Versus-Host Disease (aGvHD): Comparisons with a MAGIC Control Cohort

OPENALEX - Publications

Robert Zeiser James L.M. Ferrara Ioannis Louloudis Nikolaos Katsivelos Udo Holtick and 9 more

10.1016/j.jtct.2025.01.426 article EN Transplantation and Cellular Therapy 2025-02-01

Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD

OPENALEX - Publications

Aaron Etra Najla El Jurdi Nikolaos Katsivelos Deukwoo Kwon Stephanie Gergoudis and 33 more

Abstract Graft-versus-host disease (GVHD) is a major cause of nonrelapse mortality (NRM) after allogeneic hematopoietic cell transplantation. Algorithms containing either the gastrointestinal (GI) GVHD biomarker amphiregulin (AREG) or combination 2 GI biomarkers (suppressor tumorigenicity-2 [ST2] + regenerating family member 3 alpha [REG3α]) when measured at diagnosis are validated predictors NRM risk but have never been assessed in same patients using identical statistical methods. We serum...

10.1182/bloodadvances.2023011049 article EN cc-by-nc-nd Blood Advances 2024-06-14

Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White Patients

OPENALEX - Publications

Carlos A. Ortega Rios Muna Qayed Aaron Etra Ran Reshef Richard Newcomb and 29 more

10.1016/j.jtct.2024.08.019 article EN Transplantation and Cellular Therapy 2024-09-01

The Mount Sinai Acute Gvhd International Consortium (MAGIC) Model: An Integrated Clinical and Biomarker Grading System for Acute Graft-Versus-Host Disease (GVHD)

OPENALEX - Publications

Yu Akahoshi Nikolaos Spyrou Daniela Weber Paibel Aguayo‐Hiraldo Francis Ayuk and 28 more

10.1016/j.jtct.2023.12.087 article EN cc-by-nc-nd Transplantation and Cellular Therapy 2024-02-01

Serial Clinical and Biomarker Monitoring during Treatment Can Stratify Patients with Low Risk Gvhd

OPENALEX - Publications

Nikolaos Katsivelos Nikolaos Spyrou Daniela Weber Ingrid Vášová Francis Ayuk and 28 more

10.1182/blood-2024-204010 article EN Blood 2024-11-05

Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group

OPENALEX - Publications

Nikolaos Katsivelos Nikolaos Spyrou Daniela Weber Ingrid Vášová Francis Ayuk and 28 more

10.1016/j.jtct.2024.10.012 article EN Transplantation and Cellular Therapy 2024-12-11

Flares of Acute Graft-Versus-Host Disease: Mount Sinai Acute Gvhd International Consortium (MAGIC) Study

OPENALEX - Publications

Yu Akahoshi Nikolaos Spyrou Daniela Weber Paibel Aguayo‐Hiraldo Francis Ayuk and 28 more

10.1182/blood-2023-181900 article EN Blood 2023-11-02

A Day 14 Endpoint for Acute Gvhd Clinical Trials

OPENALEX - Publications

Nikolaos Spyrou Yu Akahoshi Steven Kowalyk George Morales Rahnuma Beheshti and 35 more

10.1182/blood-2023-172955 article EN Blood 2023-11-02

Coming Soon ...